Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000520
M. Szymański, Radosław Janicki, Magdalena Czekien, W. Szymański
Background: Ovarian cancer is the most common cause of death among patients diagnosed with reproductive organ cancers in Poland. Despite the progress and continual improvements in diagnostic techniques and methods of cancer treatment, the epidemiology and natural history of ovarian cancer remain largely unchanged. Approximately three quarters of ovarian carcinoma cases are not detected or treated until the third or fourth stage of the disease. The current routine diagnostic procedures include ultrasound examination, biochemistry marker assessments and histopathological evaluations of ovarian tissue to confirm a diagnosis. The preoperative diagnosis of ovarian cancer remains unsatisfactory, and the search for new effective methods has not provided satisfactory results.Objectives: To determine whether routine biopsy of macroscopically unchanged ovaries provides sufficient benefit.Material and methods: We conducted a clinical trial involving approximately 1,000 ovaries from which tissue samples were collected during reproductive organ surgeries, and the tissues were examined by a pathologist. Spearman’s rank correlation was used to compare the results statistically.Results: The results of the histopathological evaluation of macroscopically unchanged ovaries were normal in 99.8% of patients.Conclusion: In this context, routine biopsy of macroscopically unchanged ovaries does not provide sufficient benefit. Moreover, it may be associated with increases in surgical complications such as bleeding from the biopsy site. Therefore, biopsy of the ovaries during surgery of reproductive organs should not be performed routinely unless cancer is suspected.
{"title":"“Benefit” of Routine Ovarian Biopsy during Laparotomy for Diseases of the Female Reproductive Organs.","authors":"M. Szymański, Radosław Janicki, Magdalena Czekien, W. Szymański","doi":"10.4172/1948-5956.1000520","DOIUrl":"https://doi.org/10.4172/1948-5956.1000520","url":null,"abstract":"Background: Ovarian cancer is the most common cause of death among patients diagnosed with reproductive organ cancers in Poland. Despite the progress and continual improvements in diagnostic techniques and methods of cancer treatment, the epidemiology and natural history of ovarian cancer remain largely unchanged. Approximately three quarters of ovarian carcinoma cases are not detected or treated until the third or fourth stage of the disease. The current routine diagnostic procedures include ultrasound examination, biochemistry marker assessments and histopathological evaluations of ovarian tissue to confirm a diagnosis. The preoperative diagnosis of ovarian cancer remains unsatisfactory, and the search for new effective methods has not provided satisfactory results.Objectives: To determine whether routine biopsy of macroscopically unchanged ovaries provides sufficient benefit.Material and methods: We conducted a clinical trial involving approximately 1,000 ovaries from which tissue samples were collected during reproductive organ surgeries, and the tissues were examined by a pathologist. Spearman’s rank correlation was used to compare the results statistically.Results: The results of the histopathological evaluation of macroscopically unchanged ovaries were normal in 99.8% of patients.Conclusion: In this context, routine biopsy of macroscopically unchanged ovaries does not provide sufficient benefit. Moreover, it may be associated with increases in surgical complications such as bleeding from the biopsy site. Therefore, biopsy of the ovaries during surgery of reproductive organs should not be performed routinely unless cancer is suspected.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"9 1","pages":"69-71"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81936929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01Epub Date: 2018-03-22DOI: 10.4172/1948-5956.1000517
Nenggang Zhang, Debananda Pati
Sepin-1, a potent non-competitive inhibitor of separase, inhibits cancer cell growth, but the mechanisms of Sepin-1-mediated growth inhibition are not fully understood. Here we report that Sepin-1 hinders growth of breast cancer cells, cell migration, and wound healing. Inhibition of cell growth induced by Sepin-1 in vitro doesn't appear to be through apoptosis but rather due to growth inhibition. Following Sepin-1 treatment caspases 3 and 7 are not activated and Poly (ADP-ribose) polymerase (Parp) is not cleaved. The expression of Forkhead box protein M1 (FoxM1), a transcription factor, and its target genes in the cell cycle, including Plk1, Cdk1, Aurora A, and Lamin B1, are reduced in a Sepin-1-dependent manner. Expressions of Raf kinase family members A-Raf, B-Raf, and C-Raf also are inhibited following treatment with Sepin-1. Raf is an intermediator in the Raf-Mek-Erk signaling pathway that phosphorylates FoxM1. Activated FoxM1 can promote its own transcription via a positive feedback loop. Sepin-1-induced downregulation of Raf and FoxM1 may inhibit expression of cell cycle-driving genes, resulting in inhibition of cell growth.
{"title":"Separase Inhibitor Sepin-1 Inhibits Foxm1 Expression and Breast Cancer Cell Growth.","authors":"Nenggang Zhang, Debananda Pati","doi":"10.4172/1948-5956.1000517","DOIUrl":"10.4172/1948-5956.1000517","url":null,"abstract":"<p><p>Sepin-1, a potent non-competitive inhibitor of separase, inhibits cancer cell growth, but the mechanisms of Sepin-1-mediated growth inhibition are not fully understood. Here we report that Sepin-1 hinders growth of breast cancer cells, cell migration, and wound healing. Inhibition of cell growth induced by Sepin-1 <i>in vitro</i> doesn't appear to be through apoptosis but rather due to growth inhibition. Following Sepin-1 treatment caspases 3 and 7 are not activated and Poly (ADP-ribose) polymerase (Parp) is not cleaved. The expression of Forkhead box protein M1 (FoxM1), a transcription factor, and its target genes in the cell cycle, including Plk1, Cdk1, Aurora A, and Lamin B1, are reduced in a Sepin-1-dependent manner. Expressions of Raf kinase family members A-Raf, B-Raf, and C-Raf also are inhibited following treatment with Sepin-1. Raf is an intermediator in the Raf-Mek-Erk signaling pathway that phosphorylates FoxM1. Activated FoxM1 can promote its own transcription via a positive feedback loop. Sepin-1-induced downregulation of Raf and FoxM1 may inhibit expression of cell cycle-driving genes, resulting in inhibition of cell growth.</p>","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"10 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36115285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000509
Ariana Ferrari, A. Carvalho, J. Steluti, J. Teixeira, D. Marchioni, S. Aguiar
Objective: Calibrate the FFQ and evaluate its performance in relation to the consumption of energy, carbohydrate, protein, fat, alcohol, folate, vitamin B2, vitamin B6, vitamin B12, methionine, choline and betaine in the study population “Folate and nutrients involved in the 1-carbon cycle in the pretreatment of patients for colorectal adenocarcinoma in a referral center for oncology in southeastern Brazil.Materials and methods: For calibration, we used three 24-hour dietary recalls (R24s; n=270) and the second FFQ (n=90) collected in a previous study. The R24 data were used as a reference method and subjected to linear regression, with β1 values used as a calibration factor for the FFQ data collected.Results: Comparing the R24 data to observed FFQ data and observed FFQ data to calibrated FFQ data; the means were significantly different for all nutrients. When comparing calibrated FFQ data to R24 values, the means were statistically similar for carbohydrates, vitamin B2, vitamin B6, natural folate, synthetic folate, DFE diet and betaine.Conclusion: The calibration coefficients were low, however the reference method used may not have been the best way to eliminate measurement errors found in the FFQ.
{"title":"Calibration of Dietary Data: “Folate and Nutrients Involved in the 1-Carbon Cycle in the Pretreatment of Patients for Colorectal Adenocarcinoma in a Referral Center for Oncology in Southeastern Brazil”","authors":"Ariana Ferrari, A. Carvalho, J. Steluti, J. Teixeira, D. Marchioni, S. Aguiar","doi":"10.4172/1948-5956.1000509","DOIUrl":"https://doi.org/10.4172/1948-5956.1000509","url":null,"abstract":"Objective: Calibrate the FFQ and evaluate its performance in relation to the consumption of energy, carbohydrate, protein, fat, alcohol, folate, vitamin B2, vitamin B6, vitamin B12, methionine, choline and betaine in the study population “Folate and nutrients involved in the 1-carbon cycle in the pretreatment of patients for colorectal adenocarcinoma in a referral center for oncology in southeastern Brazil.Materials and methods: For calibration, we used three 24-hour dietary recalls (R24s; n=270) and the second FFQ (n=90) collected in a previous study. The R24 data were used as a reference method and subjected to linear regression, with β1 values used as a calibration factor for the FFQ data collected.Results: Comparing the R24 data to observed FFQ data and observed FFQ data to calibrated FFQ data; the means were significantly different for all nutrients. When comparing calibrated FFQ data to R24 values, the means were statistically similar for carbohydrates, vitamin B2, vitamin B6, natural folate, synthetic folate, DFE diet and betaine.Conclusion: The calibration coefficients were low, however the reference method used may not have been the best way to eliminate measurement errors found in the FFQ.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"6 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74562167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000555
P. Kimani, P. Mwitari, S. M. Njagi, P. Kirira, Daniel Kiboi
{"title":"In Vitro Anti-Proliferative Activity of Selected Plant Extracts Against Cervical and Prostate Cancer Cell Lines","authors":"P. Kimani, P. Mwitari, S. M. Njagi, P. Kirira, Daniel Kiboi","doi":"10.4172/1948-5956.1000555","DOIUrl":"https://doi.org/10.4172/1948-5956.1000555","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78904531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000523
Tomoaki Tanaka, K. Morimoto, T. Nakatani
Objective: Zoledronic acid (ZA) is highly effective in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. It is one of bone modifying agents (BMAs) that has been shown to exert not only inhibiting the activation of osteoclasts but also preventing the tumor cell growth, invasion and migration in some cancers. Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is a key regulator of tumor aggressiveness including invasion, epithelial-to-mesenchymal transition (EMT), dedifferentiation and resistance to chemo-drugs. However, research into a biological mechanism in the inhibitory effects of ZA on prostate cancer (PCa) metastasis is still limited. In this study, we examined its effects on tumor cell invasion and EMT via the ubiquitin-proteasomal system for NEDD9 in PC-3 cells.Methods: We assessed the expression of NEDD9 and its down-stream molecules associated with EMT in PC-3 cells exposure to ZA under the condition with/without TGF-β. By a boyden chamber assay, the suppressive effect of ZA on PC-3 cell invasion triggered by TGF-β was measured. We measured the expression levels of NEDD9 in PC-3 cells exposure to a proteasome inhibitor, MG132. In addition, we detected the effect of ZA on ubiquitinated NEDD9 using an immunoprecipitation method.Results: ZA markedly inhibited the expression of NEDD9 and its down-stream EMT molecules. Both the invasion and expression of EMT markers of PC-3 cells triggered by TGF-β were significantly suppressed by the exposure to ZA. The exposure to MG132 inhibited the degradation of NEDD9 in PC-3 cells. The further add-on of ZA enhanced the polyubiquitination of NEDD9 in PC-3 cells.Conclusion: The results from a current study indicate that ZA inhibited the invasion and expression of NEDD9 and its EMT markers, along with the enhanced degradation of ubiquitinated NEDD9 in PC-3 cells.
{"title":"Zoledronic Acid Suppresses Epithelial-to-Mesenchymal Transition and Invasion via Degradation of Ubiquitinated NEDD9 in PC-3 Prostate Cancer Cells","authors":"Tomoaki Tanaka, K. Morimoto, T. Nakatani","doi":"10.4172/1948-5956.1000523","DOIUrl":"https://doi.org/10.4172/1948-5956.1000523","url":null,"abstract":"Objective: Zoledronic acid (ZA) is highly effective in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. It is one of bone modifying agents (BMAs) that has been shown to exert not only inhibiting the activation of osteoclasts but also preventing the tumor cell growth, invasion and migration in some cancers. Neural precursor cell-expressed developmentally downregulated protein 9 (NEDD9) is a key regulator of tumor aggressiveness including invasion, epithelial-to-mesenchymal transition (EMT), dedifferentiation and resistance to chemo-drugs. However, research into a biological mechanism in the inhibitory effects of ZA on prostate cancer (PCa) metastasis is still limited. In this study, we examined its effects on tumor cell invasion and EMT via the ubiquitin-proteasomal system for NEDD9 in PC-3 cells.Methods: We assessed the expression of NEDD9 and its down-stream molecules associated with EMT in PC-3 cells exposure to ZA under the condition with/without TGF-β. By a boyden chamber assay, the suppressive effect of ZA on PC-3 cell invasion triggered by TGF-β was measured. We measured the expression levels of NEDD9 in PC-3 cells exposure to a proteasome inhibitor, MG132. In addition, we detected the effect of ZA on ubiquitinated NEDD9 using an immunoprecipitation method.Results: ZA markedly inhibited the expression of NEDD9 and its down-stream EMT molecules. Both the invasion and expression of EMT markers of PC-3 cells triggered by TGF-β were significantly suppressed by the exposure to ZA. The exposure to MG132 inhibited the degradation of NEDD9 in PC-3 cells. The further add-on of ZA enhanced the polyubiquitination of NEDD9 in PC-3 cells.Conclusion: The results from a current study indicate that ZA inhibited the invasion and expression of NEDD9 and its EMT markers, along with the enhanced degradation of ubiquitinated NEDD9 in PC-3 cells.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"23 1","pages":"80-84"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85119174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000560
Q. Ma, Feng Jiang, Leilei Wu, Wengao Liu, Ran Jia, Shuting Huang, H. Duan, P. Lin, H. Long, Lanjun Zhang, G. Ma
{"title":"The Prognostic Significance of Programmed Death Ligand-1 Expression in pT2/3N0M0 Esophageal Squamous Cell Carcinoma","authors":"Q. Ma, Feng Jiang, Leilei Wu, Wengao Liu, Ran Jia, Shuting Huang, H. Duan, P. Lin, H. Long, Lanjun Zhang, G. Ma","doi":"10.4172/1948-5956.1000560","DOIUrl":"https://doi.org/10.4172/1948-5956.1000560","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90968003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000541
Athena Li Kl, V. Wu
Background: In external beam radiotherapy of prostate cancer, the position of prostate is often affected by the bladder volume status due to their close anatomical relationship. This study aimed to evaluate the dosimetric impact of bladder volume deviation from the reference planning volume and to establish the acceptable limit of volume deviation in radiotherapy of prostate cancer. Methods: A total of 43 sets of CBCT images from prostate cancer patients treated by intensity modulated radiotherapy with full bladder were retrospectively recruited. The corresponding planning CT from these patients was retrieved from which the reference plans and 43 CBCT plans were generated respectively. The bladder volume in each plan was measured and the percentage difference of bladder volume between CBCT and planning CT (%d BV ) was calculated. The CBCT plans were stratified into 12 groups based on the magnitude of %d BV , which ranged from -75% to +75%. In each %d BV group, the dose parameters of the CBCT plans were compared with the corresponding reference plans. Results: The %d BV were ranged from -79.3% to +79.5%. The percentage differences of D 95% and V 95% of target volume between the CBCT and reference plans decreased significantly with increased %d BV . For the bladder, when the CBCT bladder volume was larger than the reference volume, increase of %d BV led to slight decrease of D mean , while when the CBCT bladder volume was smaller, the D mean increased dramatically with decreased %d BV. Conclusion: In radiotherapy of prostate cancer, increase in bladder volume from the reference planning volume led to target underdoes, while decrease in bladder volume increased the bladder dose. Keeping the treatment bladder volume within ± 20% of the reference volume can avoid unacceptable dosimetric outcome.
{"title":"Dosimetric Impact of Bladder Volume Variation in Radiotherapy for Prostate Cancer â A Pilot Study.","authors":"Athena Li Kl, V. Wu","doi":"10.4172/1948-5956.1000541","DOIUrl":"https://doi.org/10.4172/1948-5956.1000541","url":null,"abstract":"Background: In external beam radiotherapy of prostate cancer, the position of prostate is often affected by the bladder volume status due to their close anatomical relationship. This study aimed to evaluate the dosimetric impact of bladder volume deviation from the reference planning volume and to establish the acceptable limit of volume deviation in radiotherapy of prostate cancer. Methods: A total of 43 sets of CBCT images from prostate cancer patients treated by intensity modulated radiotherapy with full bladder were retrospectively recruited. The corresponding planning CT from these patients was retrieved from which the reference plans and 43 CBCT plans were generated respectively. The bladder volume in each plan was measured and the percentage difference of bladder volume between CBCT and planning CT (%d BV ) was calculated. The CBCT plans were stratified into 12 groups based on the magnitude of %d BV , which ranged from -75% to +75%. In each %d BV group, the dose parameters of the CBCT plans were compared with the corresponding reference plans. Results: The %d BV were ranged from -79.3% to +79.5%. The percentage differences of D 95% and V 95% of target volume between the CBCT and reference plans decreased significantly with increased %d BV . For the bladder, when the CBCT bladder volume was larger than the reference volume, increase of %d BV led to slight decrease of D mean , while when the CBCT bladder volume was smaller, the D mean increased dramatically with decreased %d BV. Conclusion: In radiotherapy of prostate cancer, increase in bladder volume from the reference planning volume led to target underdoes, while decrease in bladder volume increased the bladder dose. Keeping the treatment bladder volume within ± 20% of the reference volume can avoid unacceptable dosimetric outcome.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"25 1","pages":"173-177"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85308307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/1948-5956.1000558
C. Boulanger, A. Brouchet-Gomez, J. S. Gauzy, C. Munzer, L. Brugières, N. Gaspar, P. Marec-Berard, Jean, Claude Gentet, N. Corradini, F. Demeocq, L. Mansuy, M. Poirée, C. Glorion, M. Tabone, Pascale, Blouin, M. Castex, M. Pasquet
Background: Most of osteosarcomas (OS) originate on the medullary canal, and only a small proportion arises from the surface of bone. Surface OS can be divided into three distinct histologic subtypes: parosteal OS, periosteal OS and high-grade surface OS. This national retrospective study was conducted to review the treatment and clinical outcome of children surface’ OS in order to upgrade and homogenize practices. Methods: Data of 28 pediatric patients with surface OS treated in 11 French Cancer Centers (SFCE) between 1990 and 2010 were reviewed. Results: Eleven patients had parosteal, sixteen patients had periosteal and one patient had high-grade surface OS. The median age at the diagnosis was 14.3 years (range, 5.8 –17.9 years). Seven patients were male. None had metastatic disease at diagnosis. All 28 patients were treated with surgery, of whom 21 (7 parosteal, 13 periosteal and 1 high-grade tumors) received chemotherapy (adjuvant or neo-adjuvant). Three patients relapsed (local relapse for 1 patient with parosteal OS and distant relapses for two patients with periosteal OS) and four patients with periosteal OS developed a second cancer (three out of four died). The 11-year overall survival rate was 100% for parosteal OS and 63 ± 18% for periosteal OS. Conclusion: The histologic grade determines the clinical behavior and prognosis in pediatric surface OS. Complete resection is the treatment of choice regardless of pathology. Regarding prognosis, our study argues for the use of adjuvant chemotherapy in periosteal OS, as well as for oncogenetic counseling.
{"title":"Pediatrics Surface Osteosarcomas: A French Multicenter Study (SURFOS), Which is the Most Appropriate Treatment?","authors":"C. Boulanger, A. Brouchet-Gomez, J. S. Gauzy, C. Munzer, L. Brugières, N. Gaspar, P. Marec-Berard, Jean, Claude Gentet, N. Corradini, F. Demeocq, L. Mansuy, M. Poirée, C. Glorion, M. Tabone, Pascale, Blouin, M. Castex, M. Pasquet","doi":"10.4172/1948-5956.1000558","DOIUrl":"https://doi.org/10.4172/1948-5956.1000558","url":null,"abstract":"Background: Most of osteosarcomas (OS) originate on the medullary canal, and only a small proportion arises from the surface of bone. Surface OS can be divided into three distinct histologic subtypes: parosteal OS, periosteal OS and high-grade surface OS. This national retrospective study was conducted to review the treatment and clinical outcome of children surface’ OS in order to upgrade and homogenize practices. Methods: Data of 28 pediatric patients with surface OS treated in 11 French Cancer Centers (SFCE) between 1990 and 2010 were reviewed. Results: Eleven patients had parosteal, sixteen patients had periosteal and one patient had high-grade surface OS. The median age at the diagnosis was 14.3 years (range, 5.8 –17.9 years). Seven patients were male. None had metastatic disease at diagnosis. All 28 patients were treated with surgery, of whom 21 (7 parosteal, 13 periosteal and 1 high-grade tumors) received chemotherapy (adjuvant or neo-adjuvant). Three patients relapsed (local relapse for 1 patient with parosteal OS and distant relapses for two patients with periosteal OS) and four patients with periosteal OS developed a second cancer (three out of four died). The 11-year overall survival rate was 100% for parosteal OS and 63 ± 18% for periosteal OS. Conclusion: The histologic grade determines the clinical behavior and prognosis in pediatric surface OS. Complete resection is the treatment of choice regardless of pathology. Regarding prognosis, our study argues for the use of adjuvant chemotherapy in periosteal OS, as well as for oncogenetic counseling.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85839843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-19DOI: 10.4172/1948-5956-C1-116
A. Yılmaz, N. Yumuşak, A. Demir
{"title":"Effectiveness of Ononis spinosa L. for wound healing of rat oral mucosa","authors":"A. Yılmaz, N. Yumuşak, A. Demir","doi":"10.4172/1948-5956-C1-116","DOIUrl":"https://doi.org/10.4172/1948-5956-C1-116","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"86 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77406900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-08DOI: 10.4172/1948-5956.1000454
B. T. Grisez, M. Goodman, B. Lindsey
Reverse total shoulder arthroplasty (rTSA) initially faltered because of glenoid component failure. Modern design utilizes a large glenosphere component and relies upon a functional deltoid for arm elevation. We report novel use of rTSA to revise a chronically dislocating TSA. The patient underwent proximal humeral resection for chondrosarcoma, requiring sacrifice of the deltoid and all proximal insertions including the latissimus dorsi. Twoyears post-operatively, he had good stability, no pain, and was using his arm more than he had in years. rTSA is a salvage option for failed TSA, even with absent deltoid function and lack of a latissimus.
{"title":"Custom Reverse Total Shoulder Arthroplasty","authors":"B. T. Grisez, M. Goodman, B. Lindsey","doi":"10.4172/1948-5956.1000454","DOIUrl":"https://doi.org/10.4172/1948-5956.1000454","url":null,"abstract":"Reverse total shoulder arthroplasty (rTSA) initially faltered because of glenoid component failure. Modern design utilizes a large glenosphere component and relies upon a functional deltoid for arm elevation. We report novel use of rTSA to revise a chronically dislocating TSA. The patient underwent proximal humeral resection for chondrosarcoma, requiring sacrifice of the deltoid and all proximal insertions including the latissimus dorsi. Twoyears post-operatively, he had good stability, no pain, and was using his arm more than he had in years. rTSA is a salvage option for failed TSA, even with absent deltoid function and lack of a latissimus.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"1 1","pages":"430-432"},"PeriodicalIF":0.0,"publicationDate":"2017-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89539984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：